Listed

Knowles Corp: Form 10-Q for the period ended Jun 30, 2025

Filed with the SEC on Jul 29, 2025 and accepted by EDGAR at Jul 29, 2025, 16:03 ET.

Share

Management's discussion and analysis

As filed, 57,941 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements and related Notes included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are a leading manufacturer of specialty electronic components. We design parts that perform unique and critical functions for innovative technologies. Through extreme reliability, custom engineering, and scalable manufacturing, we enable businesses to succeed in the most demanding applications across medtech, defense, and industrial markets. Our high performance capacitors, radio frequency ("RF") and microwave filters, advanced medtech microphones, and balanced armature speakers, enhance the performance of our customers products to change, improve, and save lives. Our focus on the customer, combined with unique technology, proprietary manufacturing techniques, and global operational expertise, enables us to deliver innovative solutions across multiple applications. References to "Knowles," the "Company," "we," "our," or "us" refer to Knowles Corporation and its consolidated subsidiaries, unless the context otherwise requires.

We sell our products directly to original equipment manufacturers ("OEMs") and to their contract manufacturers and suppliers and through distributors worldwide.

Recent Developments

On April 2, 2025, the U.S. announced a new universal baseline tariff of 10%, plus an additional country-specific tariff for select trading partners, on all U.S. imports. These actions, and retaliatory tariffs imposed by foreign jurisdictions, have resulted in market volatility and uncertainty regarding the ultimate effect of the tariffs on global economic conditions. Based on a preliminary analysis, we do not anticipate that these factors will have a material impact on our operations; however, we continue to monitor changes in international trade relations and trade policy, including those related to tariffs, which could adversely impact our results. We are optimizing operations and leveraging existing programs and strategies to reduce the impact from tariffs. Additionally, we are taking measures to control costs and implementing pricing actions designed to mitigate the risk these policies may have on our revenues and operations.

On December 27, 2024, the Company consummated the sale and assignment of certain assets and liabilities of the Company’s Consumer MEMS Microphones ("CMM") business to Syntiant Corp. ("Syntiant") for approximately $150.0 million in total consideration, consisting of $70.0 million cash ($58.0 million in net cash received) as adjusted for agreed deductions for indebtedness, and working capital and $80.0 million in Syntiant Series D-2 preferred stock (with a fair value of $77.2 million), par value $0.0001. The Company provided $6.4 million in financing, which was utilized to fund Syntiant's requirement to have $40.0 million of cash on its balance sheet at closing. The Company will also share in certain separation costs pursuant to a credit, which Syntiant may apply to specified separation costs post-closing. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements under Part I, Item 1, "Financial Statements."

We have reclassified the results of operations and financial position of CMM to discontinued operations for all periods presented. Unless otherwise noted, our results of operations discussed below relate to continuing operations and will be impacted by the CMM divestiture.

This divestiture supports Knowles' continued transformation into an industrial technology company, consisting of its Precision Devices ("PD") and MedTech & Specialty Audio ("MSA") segments, primarily serving the defense, medtech, industrial, and electrification markets. We have incurred some amount of dis-synergies following the sale of the CMM business due to the reduced size of our company and, as a result, we have undertaken actions to help ensure that our cost structure is appropriate to support our remaining businesses.

As inventory levels in the industrial markets have recently begun to normalize, our Precision Devices segment has experienced increased bookings for the past three quarters. In addition, with bookings increasing we have seen backlog across our capacitor products increase for the past three quarters.

Non-GAAP Financial Measures

In addition to the GAAP financial measures included in this item, we have presented certain non-GAAP financial measures. We use non-GAAP measures as supplements to our GAAP results of operations in evaluating certain aspects of our business, and our executive management team and Board of Directors focus on non-GAAP items as key measures of our performance for business planning purposes. These measures assist us in comparing our performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in our opinion, do not reflect our core operating performance. We believe that our presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that we use internally for purposes of assessing our core operating performance. The Company does not consider these non-GAAP financial measures to be a substitute for the information provided by GAAP financial results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the reconciliation included herein.

Results of Operations for the Three Months Ended June 30, 2025 compared with the Three Months Ended June 30, 2024

(in millions, except per share amounts)

Three Months Ended June 30, 2025 2024
Revenues $145.9 $135.2
Gross profit $60.6 $57.8
Non-GAAP gross profit $64.5 $59.8
Earnings from continuing operations before interest and income taxes $13.8 $12.4
Adjusted earnings from continuing operations before interest and income taxes $27.7 $25.2
Provision for income taxes $3.5 $3.0
Non-GAAP provision for income taxes $4.0 $2.2
Net earnings from continuing operations $7.8 $4.8
Non-GAAP net earnings from continuing operations $21.2 $18.4
Earnings per share from continuing operations - diluted $0.09 $0.05
Non-GAAP diluted earnings per share $0.24 $0.20

Revenues

Revenues for the second quarter of 2025 were $145.9 million, compared with $135.2 million for the second quarter of 2024, an increase of $10.7 million or 7.9%. MSA revenues increased $6.3 million, primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio and hearing health markets, partially offset by lower average pricing on mature products. PD revenues increased $4.4 million due to higher demand in the electrification and defense markets, as well as higher average pricing.

Cost of Goods Sold

Cost of goods sold ("COGS") for the second quarter of 2025 was $81.7 million, compared with $77.1 million for the second quarter of 2024, an increase of $4.6 million or 6.0%. This increase was primarily due to higher shipping volumes, unfavorable product mix, production inefficiencies in our CD business as we ramp up our specialty film product line, and unfavorable inventory reserve adjustments, partially offset by company-wide product cost reductions and a reduction of CD related acquisition and production transfer costs.

Impairment Charges

During the second quarter of 2025, we recorded an impairment charge of $3.6 million to write down the carrying value of certain machinery and equipment to fair value. For additional information, refer to Note 1. Basis of Presentation to our Consolidated Financial Statements.

Restructuring Charges

During the second quarter of 2024, we recorded restructuring charges of $0.3 million within Gross profit for costs associated with transferring certain capacitors manufacturing to existing facilities to further optimize operations, and a credit of $0.1 million within Operating expenses related to previous headcount reductions, all within the PD segment. No restructuring charges were recorded during the second quarter of 2025. For additional information, refer to Note 7. Restructuring and Related Activities to our Consolidated Financial Statements.

Gross Profit and Non-GAAP Gross Profit

Gross profit for the second quarter of 2025 was $60.6 million, compared with $57.8 million for the second quarter of 2024, an increase of $2.8 million or 4.8%. Gross profit margin (gross profit as a percentage of revenues) for the second quarter of 2025 was 41.5%, compared with 42.8% for the second quarter of 2024. The increase in gross profit was primarily due to higher shipping volumes, company-wide product cost reductions, a reduction of CD related acquisition and production transfer costs, and higher factory capacity utilization in our legacy PD business, partially offset by impairment charges in 2025, unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in our CD business as we ramp up our specialty film product line. The decrease in gross profit margin is primarily due to impairment charges in 2025, unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in our CD business as we ramp up our specialty film product line, partially offset by company-wide product cost reductions, a reduction of CD related acquisition and production transfer costs, and higher factory capacity utilization in our legacy PD business.

Non-GAAP gross profit for the second quarter of 2025 was $64.5 million, compared with $59.8 million for the second quarter of 2024, an increase of $4.7 million or 7.9%. Non-GAAP gross profit margin (non-GAAP gross profit as a percentage of revenues) for the second quarter of 2025 and 2024 was 44.2%. The increase in non-GAAP gross profit was primarily due to higher shipping volumes, company-wide product cost reductions, and higher factory capacity utilization in our legacy PD business, partially offset by unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in our CD business as we ramp up our specialty film product line.

Research and Development Expenses

Research and development expenses for the second quarter of 2025 were $10.0 million, compared with $9.6 million for the second quarter of 2024, an increase of $0.4 million or 4.2%. Research and development expenses as a percentage of revenues for the second quarter of 2025 and 2024 were 6.9% and 7.1%, respectively. The increase in expenses was primarily driven by increased development activities in both our PD and MSA segments as we continue to invest in our businesses. The decrease in expenses as a percentage of revenues was driven by higher revenues.

Selling and Administrative Expenses

Selling and administrative expenses for the second quarter of 2025 were $35.9 million, compared with $35.6 million for the second quarter of 2024, an increase of $0.3 million or 0.8%. Selling and administrative expenses as a percentage of revenues for the second quarter of 2025 and 2024 were 24.6% and 26.3%, respectively. The increase in expenses was primarily driven by a change in our deferred compensation liability and higher incentive compensation, partially offset by a reduction of CD related acquisition costs and the benefits of restructuring actions. The decrease in expenses as a percentage of revenues was driven by higher revenues.

Interest Expense, net

Interest expense for the second quarter of 2025 was $2.5 million, compared with $4.6 million for the second quarter of 2024, a decrease of $2.1 million. The decrease is due to a lower outstanding revolving credit facility balance during the second quarter of 2025 and lower imputed interest expense on our Seller Note from the CD acquisition. For additional information on borrowings and interest expense, refer to Note 8. Borrowings to our Consolidated Financial Statements.

Other Expense, net

Other expense for the second quarter of 2025 was $0.9 million, compared with expense of $0.3 million for the second quarter of 2024, a change of $0.6 million. Expense in 2025 and 2024 is primarily due to unfavorable foreign currency exchange rate changes, partially offset by unrealized gains in our investment balances.

Provision for Income Taxes and Non-GAAP Provision for Income Taxes

The effective tax rate ("ETR") from continuing operations for the second quarter of 2025 and 2024 was 31.0% and 38.5%, respectively. The ETR from continuing operations for the second quarter of 2025 and 2024 includes discrete items totaling $0.1 million of tax expense. The discrete items impacting the tax provision for 2025 and 2024 are primarily attributable to stock-based compensation. Absent the discrete items, the ETR from continuing operations for the second quarter of 2025 and 2024 was 30.1% and 37.2%, respectively. The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provision for the second quarter of 2025 and 2024. The change in the ETR was due to the mix of earnings and losses by taxing jurisdictions and net discrete items.

The non-GAAP ETR from continuing operations for the second quarter of 2025 and 2024 was 15.9% and 10.7%, respectively. The non-GAAP ETR from continuing operations includes no discrete impact for the second quarter of 2025 or 2024. The change in the non-GAAP ETR was primarily due to decreased utilization of foreign tax credits compared to the prior year.

On July 4, 2025, the One Big Beautiful Bill Act was signed into U.S. federal law. As the law was enacted in the third quarter, there is no tax accounting that was recorded in the second quarter. Based on our initial analysis of the law, we do not anticipate the One Big Beautiful Bill Act having a material impact on the financial statements of Knowles in 2025 or subsequent years, but we will continue to assess and model its impact as the year progresses.

Earnings from Continuing Operations

Earnings from continuing operations for the second quarter of 2025 was $7.8 million, compared with $4.8 million for the second quarter of 2024, an improvement of $3.0 million. As described above, the improvement is primarily due to higher gross profit and lower interest expense, partially offset by higher operating expenses, other expense, and income tax expense.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

Earnings from continuing operations before interest and income taxes ("EBIT") for the second quarter of 2025 was $13.8 million, compared with $12.4 million for the second quarter of 2024, an increase of $1.4 million. EBIT margin (EBIT as a percentage of revenues) for the second quarter of 2025 was 9.5%, compared with 9.2% for the second quarter of 2024. The increase in EBIT and EBIT margin was primarily due to higher gross profit, partially offset by higher operating expenses.

Adjusted earnings before interest and income taxes ("Adjusted EBIT") from continuing operations for the second quarter of 2025 was $27.7 million, compared with $25.2 million for the second quarter of 2024, an increase of $2.5 million. Adjusted EBIT margin (Adjusted EBIT from continuing operations as a percentage of revenues) for the second quarter of 2025 was 19.0%, compared with 18.6% for the second quarter of 2024. The increase in Adjusted EBIT and Adjusted EBIT margin was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses.

Loss from Discontinued Operations, net

There was no activity for the second quarter of 2025. We recorded a loss of $264.1 million for the second quarter of 2024, primarily driven by goodwill impairment, income tax expense, and additional expenses in connection with the sale of the CMM business, partially offset by a gain on sale of fixed assets. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements.

Diluted Earnings per Share from Continuing Operations and Non-GAAP Diluted Earnings per Share from Continuing Operations

Diluted earnings per share from continuing operations was $0.09 for the second quarter of 2025, compared with $0.05 for the second quarter of 2024, an improvement of $0.04. As described above, the improvement is primarily due to higher gross profit and lower interest expense, partially offset by higher operating expenses, other expense, and income tax expense.

Non-GAAP diluted earnings per share from continuing operations was $0.24 for the second quarter of 2025, compared with $0.20 for the second quarter of 2024, an improvement of $0.04. As described above, the improvement is primarily due to higher non-GAAP gross profit and lower interest expense, partially offset by higher non-GAAP operating expenses and higher non-GAAP income tax expense.

Results of Operations for the Six Months Ended June 30, 2025 compared with the Six Months Ended June 30, 2024

(in millions, except per share amounts)

Six Months Ended June 30, 2025 2024
Revenues $278.1 $268.5
Gross profit $113.9 $111.0
Non-GAAP gross profit $119.5 $117.7
Earnings from continuing operations before interest and income taxes $17.3 $17.8
Adjusted earnings from continuing operations before interest and income taxes $49.4 $48.5
Provision for income taxes $4.7 $5.0
Non-GAAP provision for income taxes $6.8 $4.1
Net earnings from continuing operations $7.4 $3.8
Non-GAAP net earnings from continuing operations $37.4 $35.4
Earnings per share from continuing operations - diluted $0.08 $0.04
Non-GAAP diluted earnings per share $0.41 $0.38

Revenues

Revenues for the six months ended June 30, 2025 were $278.1 million, compared with $268.5 million for the six months ended June 30, 2024, an increase of $9.6 million or 3.6%. MSA revenues increased $7.0 million, primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio and hearing health markets, partially offset by lower average pricing on mature products. PD revenues increased $2.6 million due to higher demand from the medtech and electrification markets as well as higher average pricing, partially offset by lower demand from the industrial and defense markets.

Cost of Goods Sold

COGS for the six months ended June 30, 2025 was $160.1 million, compared with $156.2 million for the six months ended June 30, 2024, an increase of $3.9 million or 2.5%. This increase was primarily due to higher shipping volumes, unfavorable product mix, production inefficiencies in our CD business as we ramp up our specialty film product line, and unfavorable inventory reserve adjustments, partially offset by company-wide product cost reductions and a reduction of CD related acquisition and production transfer costs.

Impairment Charges

During the six months ended June 30, 2025, we recorded an impairment charge of $3.6 million to write down the carrying value of certain machinery and equipment to fair value. For additional information, refer to Note 1. Basis of Presentation to our Consolidated Financial Statements.

Restructuring Charges

During the six months ended June 30, 2025, we recorded restructuring charges of $0.5 million within Gross profit and $2.4 million within Operating expenses related to headcount reductions across the Company to rightsize operating expenses subsequent to the sale of the CMM business. For additional information, refer to Note 7. Restructuring and Related Activities to our Consolidated Financial Statements.

During the six months ended June 30, 2024, we recorded restructuring charges of $1.3 million within Gross profit and $1.4 million within Operating expenses related to transferring certain capacitors manufacturing to existing facilities to further optimize operations, all within our PD segment. For additional information, refer to Note 7. Restructuring and Related Activities to our Consolidated Financial Statements.

Gross Profit and Non-GAAP Gross Profit

Gross profit for the six months ended June 30, 2025 was $113.9 million, compared with $111.0 million for the six months ended June 30, 2024, an increase of $2.9 million or 2.6%. Gross profit margin (gross profit as a percentage of revenues) for the six months ended June 30, 2025 was 41.0%, compared with 41.3% for the six months ended June 30, 2024. The increase in gross profit was primarily due to higher shipping volumes, company-wide product cost reductions, a reduction of CD related acquisition and production transfer costs, and lower restructuring charges, partially offset by impairment charges in 2025, unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in our CD business as we ramp up our specialty film product line. The decrease in gross profit margin is primarily due to impairment charges in 2025, unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in our CD business as we ramp up our specialty film product line, partially offset by company-wide product cost reductions, a reduction of CD related acquisition and production transfer costs, and lower restructuring charges.

Non-GAAP gross profit for the six months ended June 30, 2025 was $119.5 million, compared with $117.7 million for the six months ended June 30, 2024, an increase of $1.8 million or 1.5%. Non-GAAP gross profit margin (non-GAAP gross profit as a percentage of revenues) for the six months ended June 30, 2025 was 43.0%, compared with 43.8% for the six months ended June 30, 2024. The increase in non-GAAP gross profit was primarily due to higher shipping volumes and company-wide product cost reductions, partially offset by unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in our CD business as we ramp up our specialty film product line. The decrease in non-GAAP gross profit margin is primarily due to unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in our CD business as we ramp up our specialty film product line, partially offset by company-wide product cost reductions.

Research and Development Expenses

Research and development expenses for the six months ended June 30, 2025 were $19.7 million, compared with $19.0 million for the six months ended June 30, 2024, an increase of $0.7 million or 3.7%. Research and development expenses as a percentage of revenues for the six months ended June 30, 2025 and 2024 was 7.1%. The increase in expenses was primarily driven by increased development activities in both our MSA and PD segments as we continue to invest in our businesses.

Selling and Administrative Expenses

Selling and administrative expenses for the six months ended June 30, 2025 were $73.1 million, compared with $72.9 million for the six months ended June 30, 2024, an increase of $0.2 million or 0.3%. Selling and administrative expenses as a percentage of revenues for the six months ended June 30, 2025 and 2024 were 26.3% and 27.2%, respectively. The increase in expenses was primarily driven by the acceleration of stock-based compensation expense for employees who are nearing or have reached retirement eligibility and higher incentive compensation, partially offset by the benefits of restructuring actions, a reduction of CD related acquisition costs, and reduced intangible amortization costs. The decrease in expenses as a percentage of revenues was driven by higher revenues.

Interest Expense, net

Interest expense for the six months ended June 30, 2025 was $5.2 million, compared with $9.0 million for the six months ended June 30, 2024, a decrease of $3.8 million. The decrease is due to a lower outstanding revolving credit facility balance during the six months ended June 30, 2025 and lower imputed interest expense on our Seller Note from the CD acquisition. For additional information on borrowings and interest expense, refer to Note 8. Borrowings to our Consolidated Financial Statements.

Other Expense (Income), net

Other expense for the six months ended June 30, 2025 was $1.4 million, compared with income of $0.1 million for the six months ended June 30, 2024, a change of $1.5 million. Expense for the six months ended June 30, 2025 primarily represents unfavorable foreign currency changes, partially offset by unrealized gains in our investment balances. Income in the six months ended June 30, 2024 primarily represents unrealized gains in our investment balances, partially offset by unfavorable foreign currency changes.

Provision for Income Taxes and Non-GAAP Provision for Income Taxes

The ETR from continuing operations for the six months ended June 30, 2025 and 2024 was 38.8% and 56.8%, respectively. The ETR from continuing operations for the six months ended June 30, 2025 and 2024 includes discrete items totaling $0.3 million of tax benefit and $0.5 million of tax expense, respectively. The discrete items impacting the tax provision for 2025 and 2024 are primarily attributable to stock-based compensation. Absent the discrete items, the ETR from continuing operations for the six months ended June 30, 2025 and 2024 was 41.3% and 51.1%, respectively. The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provision for the six months ended June 30, 2025 and 2024. The change in the ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.

The non-GAAP ETR from continuing operations for the six months ended June 30, 2025 and 2024 was 15.4% and 10.4%, respectively. The non-GAAP ETR from continuing operations includes no discrete impact for the six months ended June 30, 2025 and 2024. The change in the non-GAAP ETR was primarily due to decreased utilization of foreign tax credits compared to the prior year.

Earnings from Continuing Operations

Earnings from continuing operations for the six months ended June 30, 2025 was $7.4 million, compared with $3.8 million for the six months ended June 30, 2024, an improvement of $3.6 million. As described above, the improvement is primarily due to lower interest expense and higher gross profit, partially offset by higher operating expenses and other expense in the six months ended June 30, 2025 compared to other income for the six months ended June 30, 2024.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

EBIT for the six months ended June 30, 2025 was $17.3 million, compared with $17.8 million for the six months ended June 30, 2024, a decrease of $0.5 million. EBIT margin for the six months ended June 30, 2025 was 6.2%, compared with 6.6% for the six months ended June 30, 2024. The decrease in EBIT was primarily due to higher operating and other expenses, partially offset by higher gross profit. The decrease in EBIT margin was primarily due to higher operating expenses, increased other expenses, and lower gross profit margin.

Adjusted EBIT from continuing operations for the six months ended June 30, 2025 was $49.4 million, compared with $48.5 million for the six months ended June 30, 2024, an increase of $0.9 million. Adjusted EBIT margin for the six months ended June 30, 2025 was 17.8%, compared with 18.1% for the six months ended June 30, 2024. The increase in Adjusted EBIT was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses. The decrease in Adjusted EBIT margin was primarily driven by higher non-GAAP operating expenses and lower gross profit margin.

Loss from Discontinued Operations, net

Loss from discontinued operations for the six months ended June 30, 2025 was $1.6 million, compared with a loss of $260.6 million for the six months ended June 30, 2024, an increase of $259.0 million. Loss from discontinued operations for the six months ended June 30, 2025 was primarily driven by unfavorable working capital adjustments. Loss from discontinued operations for the six months ended June 30, 2024 was primarily driven by goodwill impairment, income tax expense, and additional expenses in connection with the sale of the CMM business, partially offset by the gain on sale of technology and gain on sale of fixed assets. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements.

Diluted Earnings per Share from Continuing Operations and Non-GAAP Diluted Earnings per Share from Continuing Operations

Diluted earnings per share from continuing operations was $0.08 for the six months ended June 30, 2025, compared with earnings of $0.04 for the six months ended June 30, 2024, an improvement of $0.04. As described above, the improvement is primarily due to lower interest and income tax expense, partially offset by higher operating expenses and other expense in the six months ended June 30, 2025 compared to other income for the six months ended June 30, 2024.

Non-GAAP diluted earnings per share from continuing operations was $0.41 for the six months ended June 30, 2025 and $0.38 for the six months ended June 30, 2024, an improvement of $0.03. As described above, the improvement is primarily due to lower interest expense and higher non-GAAP gross profit, partially offset by higher non-GAAP income tax expense and non-GAAP operating expenses.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (1)

(in millions, except per share amounts)

Three Months Ended June 30, 2025 2024 Six Months Ended June 30, 2025 2024
Gross profit $60.6 $57.8 $113.9 $111.0
Stock-based compensation expense 0.3 0.4 0.8 0.8
Impairment charges 3.6 — 3.6 —
Restructuring charges — 0.3 0.5 1.3
Production transfer costs (2) 0.2 0.7 0.3 1.5
Acquisition-related costs (3) — 0.6 — 2.0
Transition services credit (4) (0.2) — (0.4) —
Other (5) — — 0.8 1.1
Non-GAAP gross profit $64.5 $59.8 $119.5 $117.7
Net earnings from continuing operations $7.8 $4.8 $7.4 $3.8
Interest expense, net 2.5 4.6 5.2 9.0
Provision for income taxes 3.5 3.0 4.7 5.0
Earnings from continuing operations before interest and income taxes 13.8 12.4 17.3 17.8
Stock-based compensation expense 6.3 5.9 16.5 11.0
Intangibles amortization expense 4.1 4.2 8.1 8.6
Impairment charges 3.6 — 3.6 —
Restructuring charges — 0.2 2.9 2.7
Production transfer costs (2) 0.2 0.8 0.4 1.6
Acquisition-related costs (3) 0.2 2.0 0.7 6.2
Transition services credit (4) (0.5) — (1.2) —
Other (5) — (0.3) 1.1 0.6
Adjusted earnings from continuing operations before interest and income taxes $27.7 $25.2 $49.4 $48.5
Provision for income taxes $3.5 $3.0 $4.7 $5.0
Income tax effects of non-GAAP reconciling adjustments (6) 0.5 (0.8) 2.1 (0.9)
Non-GAAP provision for income taxes $4.0 $2.2 $6.8 $4.1
Net earnings from continuing operations $7.8 $4.8 $7.4 $3.8
Non-GAAP reconciling adjustments (7) 13.9 12.8 32.1 30.7
Income tax effects of non-GAAP reconciling adjustments (6) 0.5 (0.8) 2.1 (0.9)
Non-GAAP net earnings $21.2 $18.4 $37.4 $35.4
Diluted earnings per share from continuing operations $0.09 $0.05 $0.08 $0.04
Earnings per share non-GAAP reconciling adjustment (8) 0.15 0.15 0.33 0.34
Non-GAAP diluted earnings per share $0.24 $0.20 $0.41 $0.38
Diluted average shares outstanding 87.6 89.9 88.3 90.4
Non-GAAP adjustment (9) 2.2 3.3 1.9 2.6
Non-GAAP diluted average shares outstanding (9) 89.8 93.2 90.2 93.0

33

(1) In addition to the GAAP financial measures included herein, Knowles has presented certain non-GAAP financial measures that exclude certain amounts that are included in the most directly comparable GAAP measures. Knowles believes that non-GAAP measures are useful as supplements to its GAAP results of operations to evaluate certain aspects of its operations and financial performance, and its management team primarily focuses on non-GAAP items in evaluating Knowles' performance for business planning purposes. Knowles also believes that these measures assist it with comparing its performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in Knowles' opinion, do not reflect its core operating performance. Knowles believes that its presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that Knowles uses internally for purposes of assessing its core operating performance.

(2) Production transfer costs represent duplicate costs incurred to migrate manufacturing to facilities primarily within the United States. These amounts are included in the corresponding Gross profit and Earnings from continuing operations before interest and income taxes for each period presented.

(3) These expenses are related to the acquisition of CD by the PD segment. These expenses include ongoing costs to facilitate integration, the amortization of fair value adjustments to inventory, and costs incurred by the Company to carry out this transaction.

(4) Transition services represent amounts charged to Syntiant in connection with post-closing transition and separation costs

(5) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.

(6) Income tax effects of non-GAAP reconciling adjustments are calculated using the applicable tax rates in the jurisdictions of the underlying adjustments.

(7) The non-GAAP reconciling adjustments to reconcile Earnings from continuing operations before interest and income taxes to Adjusted earnings from continuing operations before interest and income taxes include stock-based compensation expense, intangibles amortization expense, restructuring charges, production transfer costs, acquisition-related costs, and other expenses, partially offset by a credit to transition services.

(8) Non-GAAP diluted earnings per share includes reconciling adjustments on non-GAAP net earnings.

(9) The number of shares used in the diluted per share calculations on a non-GAAP basis excludes the impact of stock-based compensation expense expected to be incurred in future periods and not yet recognized in the financial statements, which would otherwise be assumed to be used to repurchase shares under the GAAP treasury stock method.

Segment Results of Operations for the Three Months Ended June 30, 2025 compared with the Three Months Ended June 30, 2024

The following is a summary of the results of operations of our two reportable segments: Precision Devices and Medtech & Specialty Audio.

See Note 14. Segment Information to the Consolidated Financial Statements for (i) a reconciliation of segment revenues to our consolidated revenues and (ii) a reconciliation of segment adjusted earnings before interest and income taxes to our consolidated earnings before income taxes and discontinued operations.

Precision Devices

(in millions)

Three Months Ended June 30, 2025 Percent of Revenues 2024 Percent of Revenues
Revenues $78.5 $74.1
Earnings from continuing operations before interest and income taxes $8.2 10.4% $4.2 5.7%
Stock-based compensation expense 1.2 0.7
Intangibles amortization expense 4.1 4.2
Restructuring charges — 0.2
Production transfer costs (1) 0.2 0.8
Acquisition-related costs (2) 0.2 1.7
Adjusted earnings from continuing operations before interest and income taxes $13.9 17.7% $11.8 15.9%
(1) Production transfer costs represent costs incurred to migrate manufacturing to existing facilities.
(2) These expenses are related to the acquisition of CD. These expenses include ongoing costs to facilitate integration.

Revenues

PD revenues were $78.5 million for the second quarter of 2025, compared with $74.1 million for the second quarter of 2024, an increase of $4.4 million or 5.9%. Revenues increased due to higher demand in the electrification and defense markets, as well as higher average pricing.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

PD EBIT was $8.2 million for the second quarter of 2025, compared with $4.2 million for the second quarter of 2024, an increase of $4.0 million. EBIT margin for the second quarter of 2025 was 10.4%, compared to 5.7% for the second quarter of 2024. The increases were due to higher gross profit primarily driven by higher shipping volumes, increased factory capacity utilization in our legacy PD business, product cost reductions, a reduction of CD related acquisition and production transfer costs, and higher average pricing, partially offset by production inefficiencies in our CD business as we ramp up our specialty film product line, unfavorable product mix, and unfavorable inventory reserve adjustments.

PD Adjusted EBIT was $13.9 million for the second quarter of 2025, compared with $11.8 million for the second quarter of 2024, an increase of $2.1 million. Adjusted EBIT margin for the second quarter of 2025 was 17.7%, compared with 15.9% for the second quarter of 2024. The increases were due to higher non-GAAP gross profit. The non-GAAP gross profit increase was driven by higher shipping volumes, increased factory capacity utilization in our legacy PD business, product cost reductions, and higher average pricing, partially offset by production inefficiencies in our CD business as we ramp up our specialty film product line, unfavorable product mix, and unfavorable inventory reserve adjustments.

MedTech & Specialty Audio

(in millions)

Three Months Ended June 30, 2025 Percent of Revenues 2024 Percent of Revenues
Revenues $67.4 $61.1
Earnings from continuing operations before interest and income taxes $21.0 31.2% $24.1 39.4%
Stock-based compensation expense 1.5 1.0
Impairment charges 3.6 —
Adjusted earnings from continuing operations before interest and income taxes $26.1 38.7% $25.1 41.1%

Revenues

MSA revenues were $67.4 million for the second quarter of 2025, compared with $61.1 million for the second quarter of 2024, an increase of $6.3 million or 10.3%. Revenues increased primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio and hearing health markets, partially offset by lower average pricing on mature products.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

MSA EBIT was $21.0 million for the second quarter of 2025, compared with $24.1 million for the second quarter of 2024, a decrease of $3.1 million. EBIT margin for the second quarter of 2025 was 31.2%, compared with 39.4% for the second quarter of 2024. The decreases were primarily due to lower gross profit and higher operating expenses. The gross profit decrease was primarily due to impairment charges recorded in the second quarter of 2025, lower average pricing on mature products, unfavorable product mix, higher factory costs, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by higher shipping volumes. The increase in operating expenses was primarily driven by higher stock-based compensation and legal costs.

MSA Adjusted EBIT was $26.1 million for the second quarter of 2025, compared with $25.1 million for the second quarter of 2024, an increase of $1.0 million. Adjusted EBIT margin for the second quarter of 2025 was 38.7%, compared to 41.1% for the second quarter of 2024. The increase in adjusted EBIT was primarily due to higher non-GAAP gross profit driven by higher shipping volumes, partially offset by lower average pricing on mature products, unfavorable product mix, and higher factory costs. The decrease in Adjusted EBIT margin was primarily due to lower average pricing on mature products, unfavorable product mix, higher factory costs, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant.

Segment Results of Operations for the Six Months Ended June 30, 2025 compared with the Six Months Ended June 30, 2024

Precision Devices

(in millions)

Six Months Ended June 30, 2025 Percent of Revenues 2024 Percent of Revenues
Revenues $151.0 $148.4
Earnings before interest and income taxes $11.4 7.5% $2.1 1.4%
Stock-based compensation expense 2.6 0.8
Intangibles amortization expense 8.1 8.6
Restructuring charges 1.4 2.7
Production transfer costs (1) 0.4 1.6
Acquisition-related costs (2) 0.7 5.3
Other — 0.5
Adjusted earnings before interest and income taxes $24.6 16.3% $21.6 14.6%
(1) Production transfer costs represent costs incurred to migrate manufacturing to existing facilities.
(2) These expenses are related to the acquisition of CD. These expenses include ongoing costs to facilitate integration and the amortization of fair value adjustments to inventory.

Revenues

PD revenues were $151.0 million for the six months ended June 30, 2025, compared with $148.4 million for the six months ended June 30, 2024, an increase of $2.6 million or 1.8%. Revenues increased due to higher demand from the medtech and electrification markets, as well as higher average pricing, partially offset by lower demand from the industrial and defense markets.

Earnings and Adjusted Earnings Before Interest and Income Taxes

PD EBIT was $11.4 million for the six months ended June 30, 2025, compared with $2.1 million for the six months ended June 30, 2024, an increase of $9.3 million. EBIT margin for the six months ended June 30, 2025 was 7.5%, compared to 1.4% for six months ended June 30, 2024. The increases were primarily due to higher gross profit and lower operating expenses. The gross profit increase was primarily driven by product cost reductions, lower CD related acquisition and production transfer costs, increased factory capacity utilization in our legacy PD business, reduced restructuring charges, and higher average pricing, partially offset by production inefficiencies in our CD business as we ramp up our specialty film product line, unfavorable product mix, and unfavorable inventory reserve adjustments. The decrease in operating expenses was primarily driven by the benefits of restructuring actions, a reduction of CD acquisition related costs, and lower intangible amortization costs, partially offset by higher stock-based compensation.

PD Adjusted EBIT was $24.6 million for the six months ended June 30, 2025, compared with $21.6 million for the six months ended June 30, 2024, an increase of $3.0 million. Adjusted EBIT margin for the six months ended June 30, 2025 was 16.3%, compared with 14.6% for the six months ended June 30, 2024. The increases were primarily due to higher non-GAAP gross profit and lower non-GAAP operating expenses. The non-GAAP gross profit increase was primarily driven by product cost reductions, increased factory capacity utilization in our legacy PD business, and higher average pricing, partially offset by production inefficiencies in our CD business as we ramp up our specialty film product line, unfavorable product mix, and unfavorable inventory reserve adjustments. The decrease in non-GAAP operating expenses was primarily driven by the benefits of restructuring actions.

MedTech & Specialty Audio

(in millions)

Six Months Ended June 30, 2025 Percent of Revenues 2024 Percent of Revenues
Revenues $127.1 $120.1
Earnings before interest and income taxes $40.3 31.7% $46.9 39.1%
Stock-based compensation expense 3.2 2.0
Impairment charges 3.6 —
Restructuring charges 0.3 —
Adjusted earnings before interest and income taxes $47.4 37.3% $48.9 40.7%

Revenues

MSA revenues were $127.1 million for the six months ended June 30, 2025, compared with $120.1 million for the six months ended June 30, 2024, an increase of $7.0 million or 5.8%. Revenues increased primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio and hearing health markets, partially offset by lower average pricing on mature products.

Earnings and Adjusted Earnings Before Interest and Income Taxes

MSA EBIT was $40.3 million for the six months ended June 30, 2025, compared with $46.9 million for the six months ended June 30, 2024, a decrease of $6.6 million or 14.1%. EBIT margin for the six months ended June 30, 2025 was 31.7%, compared with 39.1% for the six months ended June 30, 2024. The decreases were primarily due to lower gross profit and higher operating expenses. The gross profit decrease was primarily due to impairment charges recorded in the second quarter of 2025, lower average pricing on mature products, unfavorable product mix, higher factory costs, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by higher shipping volumes. The increase in operating expenses was primarily driven by higher stock-based compensation and legal costs.

MSA Adjusted EBIT was $47.4 million for the six months ended June 30, 2025, compared with $48.9 million for the six months ended June 30, 2024, a decrease of $1.5 million. Adjusted EBIT margin for the six months ended June 30, 2025 was 37.3%, compared to 40.7% for the six months ended June 30, 2024. The decreases were primarily due to lower non-GAAP gross profit and higher non-GAAP operating expenses. The decrease in non-GAAP gross profit was primarily due to lower average pricing on mature products, unfavorable product mix, higher factory costs, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by higher shipping volumes. The increase in non-GAAP operating expenses was primarily driven by higher legal costs.

Liquidity and Capital Resources

Historically, we have generated and expect to continue to generate positive cash flow from operations. Our ability to fund our operations and capital needs will depend on our ongoing ability to generate cash from operations and access to capital markets. We believe that our future cash flow from operations and access to capital markets will provide adequate resources to fund our working capital needs, capital expenditures, strategic investments, and share repurchases. We have secured a revolving line of credit in the United States from a syndicate of commercial banks to provide additional liquidity. Furthermore, if we were to require additional cash above and beyond our cash on the balance sheet, the free cash flow generated by the business, and availability under our revolving credit facility, we would most likely seek to raise long-term financing through the U.S. debt or bank markets.

Due to the global nature of our operations, a portion of our cash is generated and typically held outside the United States. Our cash and cash equivalents totaled $103.2 million and $130.1 million at June 30, 2025 and December 31, 2024, respectively. Of these amounts, cash held by our non-U.S. operations totaled $31.8 million and $92.4 million as of June 30, 2025 and December 31, 2024, respectively. To the extent we repatriate these funds to the U.S., we may be required to pay U.S. state income taxes and applicable foreign withholding taxes on those amounts during the period when such repatriation occurs. Management will continue to reassess our need to repatriate the earnings of our foreign subsidiaries.

On December 27, 2024, we completed the sale of the CMM segment to Syntiant for approximately $141.9 million in total consideration, consisting of $63.6 million in cash ($58.0 million net of cash sold), $1.1 million for estimated purchase price adjustments, and Series D-2 preferred stock of Syntiant with a fair value of $77.2 million. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements. We will also share in certain separation costs pursuant to a credit for up to $13.5 million, which the buyer may apply to specified separation costs post-closing. For additional information, refer to Note 1. Basis of Presentation.

On February 24, 2020, we announced that our Board of Directors had authorized a share repurchase program of up to $100.0 million of our common stock. On April 28, 2022, we announced that our Board of Directors had increased the authorization by up to $150.0 million in additional aggregate value. On February 13, 2025, the Company announced another authorization increase of up to $150.0 million in additional aggregate value. At June 30, 2025, we have $159.0 million remaining that may yet be repurchased under our share repurchase program. The timing and amount of any shares repurchased will be determined by us based on our evaluation of market conditions and other factors, and will be made in accordance with applicable securities laws in either the open market or in privately negotiated transactions. We are not obligated to purchase any shares under the program, and the program may be suspended or discontinued at any time. Any shares repurchased will be held as treasury stock. During the six months ended June 30, 2025 and 2024, the Company repurchased 2,182,462 and 1,432,989 shares of common stock, respectively, for a total of $35.0 million and $25.0 million, respectively.

Cash flows from operating, investing, and financing activities as reflected in our Consolidated Statements of Cash Flows and are presented on a consolidated basis, including discontinued operations. Cash flows are summarized in the following table:

(in millions)

Net cash flows provided by (used in): Six Months Ended June 30, 2025 2024
Operating activities $37.7 $42.2
Investing activities (8.6) 0.6
Financing activities (56.5) (46.0)
Effect of exchange rate changes on cash and cash equivalents 0.5 (0.1)
Net decrease in cash and cash equivalents $(26.9) $(3.3)

39

Operating Activities

Cash provided by operating activities adjusts net earnings for certain non-cash items, including impairment charges, depreciation expense, amortization of intangible assets, stock-based compensation, changes in deferred income taxes, and the effects of changes in operating assets and liabilities. Excluding non-cash items, the decrease in cash provided by operating activities in 2025 is primarily due to $29.3 million of payments to settle supplier obligations and separation costs related to the CMM business and higher restructuring payments, partially offset by customer prepayments of $19.8 million and lower incentive compensation payments.

Investing Activities

The cash used in investing activities during 2025 was driven by capital expenditures, which is primarily driven by capacity expansion related to our specialty film product line and cost savings. The cash provided by investing activities during 2024 was primarily driven by proceeds from the sale of intellectual property, partially offset by capital expenditures to support product innovation and cost savings.

In 2025, we expect capital expenditures to be in the range of 4% to 6% of revenues.

Financing Activities

Cash used in financing activities during 2025 was primarily related to $35.0 million of repurchases of common stock, $15.0 million of payments on the revolving credit facility, and $6.9 million of tax payments related to net share settlement of equity awards, partially offset by proceeds of $0.6 million from the exercise of options. Cash used in financing activities during 2024 was primarily related to $25.0 million of repurchases of common stock, $14.0 million of net payments on the revolving credit facility, and $5.9 million payment of taxes related to net share settlement of equity awards.

Adjusted Free Cash Flow

In addition to measuring cash flow generation based on the operating, investing, and financing classifications included in the Consolidated Statement of Cash Flows (including discontinued operations), Knowles also measures adjusted free cash flow and adjusted free cash flow as a percentage of revenues. Adjusted free cash flow is defined as non-GAAP net cash attributable to continuing operations less non-GAAP capital expenditures attributable to continuing operations. Non-GAAP net cash attributable to continuing operations is defined as net cash provided by operating activities less amounts generated or utilized by discontinued operations. Non-GAAP capital expenditures attributable to continuing operations is defined as capital expenditures less amounts attributable to discontinued operations. Knowles believes these measures are helpful in measuring its cash generated from its continuing operations that is available to repay debt, fund acquisitions, and repurchase Knowles common stock. Adjusted free cash flow and adjusted free cash flow as a percentage of revenues are not presented in accordance with GAAP and may not be comparable to similarly titled measures used by other companies in our industry. As such, adjusted free cash flow and adjusted free cash flow as a percentage of revenues should not be considered in isolation from, or as an alternative to, any other liquidity measures determined in accordance with GAAP.

The following table reconciles our adjusted free cash flow to cash flow provided by operating activities:

(in millions)

Six Months Ended June 30, 2025 2024
Net cash provided by operating activities $37.7 $42.2
Less: amounts utilized by discontinued operations 29.3 0.2
Non-GAAP net cash attributable to continuing operations 67.0 42.4
Capital expenditures (9.1) (6.6)
Less: amounts attributable to discontinued operations — 0.7
Non-GAAP capital expenditures attributable to continuing operations (9.1) (5.9)
Non-GAAP net cash attributable to continuing operations 67.0 42.4
Non-GAAP capital expenditures attributable to continuing operations (9.1) (5.9)
Adjusted free cash flow $57.9 $36.5
Adjusted free cash flow as a % of revenues 20.8% 13.6%

In 2025 we generated adjusted free cash flow of $57.9 compared to adjusted free cash flow of $36.5 million in 2024. The increase in adjusted free cash flow in 2025 was primarily due to customer prepayments of $19.8 million and lower incentive compensation payments, partially offset by higher restructuring payments.

Contingent Obligations

We are involved in various legal proceedings, claims, and investigations arising in the ordinary course of business. Legal contingencies are discussed in Note 13. Commitments and Contingent Liabilities to our Consolidated Financial Statements.

Critical Accounting Estimates

This discussion and analysis of results of operations and financial condition is based on our Consolidated Financial Statements, which have been prepared in conformity with U.S. GAAP. The preparation of these financial statements requires the use of estimates and assumptions related to the reporting of assets, liabilities, revenues, expenses, and related disclosures. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements. Estimates are revised periodically. Actual results could differ from these estimates.

The information concerning our critical accounting estimates can be found under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 13, 2025. There are no material changes in our previously reported critical accounting estimates.

Recent Accounting Standards

The issuance of recent accounting standards, as included in Note 2. Recent Accounting Standards to our Consolidated Financial Statements, is not expected to have a significant impact on our revenue, earnings, or liquidity.

Market risk

As filed, 431 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

During the six months ended June 30, 2025, there were no material changes to the information on market risk exposure disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024. For a discussion of our exposure to market risk as of December 31, 2024, refer to Item 7A, Quantitative and Qualitative Disclosures about Market Risk, contained in our Annual Report on Form 10-K for the year ended December 31, 2024.

Controls and procedures

As filed, 2,964 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management has evaluated, under the supervision and with the participation of our chief executive officer ("CEO") and chief financial officer ("CFO"), the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on that evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the second quarter of 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including the CEO and CFO, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, will be detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by intentionally falsified documentation, by collusion of two or more individuals within Knowles or third parties, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Risk factors

As filed, 183 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes from the risk factors previously disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-04-01 to 2025-06-30$145.9mus-gaap:Revenues
Revenue6 months2025-01-01 to 2025-06-30$278.1mus-gaap:Revenues
Cost of revenue3 months2025-04-01 to 2025-06-30$81.7mus-gaap:CostOfRevenue
Cost of revenue6 months2025-01-01 to 2025-06-30$160.1mus-gaap:CostOfRevenue
Gross profit3 months2025-04-01 to 2025-06-30$60.6mus-gaap:GrossProfit
Gross profit6 months2025-01-01 to 2025-06-30$113.9mus-gaap:GrossProfit
Research and development3 months2025-04-01 to 2025-06-30$10.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2025-01-01 to 2025-06-30$19.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-04-01 to 2025-06-30$35.9mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2025-01-01 to 2025-06-30$73.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-04-01 to 2025-06-30$14.7mus-gaap:OperatingIncomeLoss
Operating income6 months2025-01-01 to 2025-06-30$18.7mus-gaap:OperatingIncomeLoss
Income tax3 months2025-04-01 to 2025-06-30$3.5mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2025-01-01 to 2025-06-30$4.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-04-01 to 2025-06-30$7.8mus-gaap:NetIncomeLoss
Net income6 months2025-01-01 to 2025-06-30$5.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-04-01 to 2025-06-30$0.09us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2025-01-01 to 2025-06-30$0.07us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-04-01 to 2025-06-30$0.09us-gaap:EarningsPerShareBasic
Basic EPS6 months2025-01-01 to 2025-06-30$0.07us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-04-01 to 2025-06-3087,600,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2025-01-01 to 2025-06-3088,300,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2025-01-01 to 2025-06-30$37.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2025-01-01 to 2025-06-30$9.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases6 months2025-01-01 to 2025-06-30$35.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2025-06-30$103.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-06-30$334.8mus-gaap:AssetsCurrent
Total assetsAt period end2025-06-30$1.09bnus-gaap:Assets
Current liabilitiesAt period end2025-06-30$167.2mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2025-06-30$119.0mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2025-06-30$71.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2025-06-30$746.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001587523-25-000066. Last ingested by Listed: Nov 11, 2026, 02:23 ET. Listed shows no prices and gives no investment advice.